Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Zhang X, Zhao R, Qi Y, Yan X, Qi G, et al.
…regimen has a long treatment cycle and is prone to multiple drug resistance. Anti-tuberculosis drugs and latent tuberculosis infection (LTBI) resistance are increasing year by year, and new targets and new bioactive compounds are urgently needed to treat this disease. This review…
Ketan N Malu, Avinash Lamb
…b>Background:</b> Isoniazid(INH) is an important first line drug in the management of active and latent TB. It’s widespread use and lack of diagnostic testing has resulted in increase in prevalence of Hr-TB, either alone or in combination with other drugs. katG and inhA mutations…
…-tion, the growth of severe forms of the disease, caused by drug-resis tant strains of mycobacterium tuberculosis, continues. The drug resistance of the pathogen, which WHO has de signated as a global threat, the crisis of clas-sical antibio tic therapy dictate the need to develo…
N. Rao, Ruchi Bhosale
…ch year despite medical breakthroughs. Long-term therapies, drug-resistant TB strains, and co-infections with conditions like HIV necessitate novel approaches. The use of Mycobacterium tuberculosis (Mtb) efflux pumps, which actively expel drugs and decrease their effectiveness, i…
Rohde KH, Sorci L
Given the upsurge of drug-resistant tuberculosis worldwide, there is much focus on developing novel drug combinations allowing shorter treatment duration and a lower toxicity profile. Nicotinamide adenine dinucleotide (NAD) biosynthesis targeting is acknowledged as a promising st…
KN Malu, AR Lamb
…>Background</h3> Isoniazid (INH) is an important first line drug in the management of active and latent TB. Its widespread use and lack of diagnostic testing has resulted in an increase in the prevalence of Hr-TB, either alone or in combination with other drugs. katG and inhA mut…
Katherine Timboe, J Brooks Jackson, Greta L Becker
…hough effective treatments are available, treatment length, drug toxicity, and the emergence of drug-resistant strains have challenged TB control efforts. Current clinical trials are focused on developing shorter, safer, and more effective regimens that incorporate both new and r…
…ocated a dormant "hi-bernation" with a lack of replication. Drug tolerance, phenotypic resistance, which differs from genetically determined drug resistance in that persistent mycobac-teria with sharply reduced metabolism simply do not respond to antibacterial drugs. L-transforma…
Delia Goletti, Seif Al-Abri, Giovanni Battista Migliori, Cecilia S. Lindestam Arlehamn, Pranabashis Haldar, et al.
… deaths yearly, mostly in low- and middle-income countries. Drug-resistant TB is the leading cause of death owing to antimicrobial resistant disease in the world today and is a growing global health security threat, with hundreds of thousands of people affected every year [1World…
Adrian Martineau, PhD
…%. Preventive therapy (e.g. a 6-month course of the anti-TB drug isoniazid) is effective in reducing risk of progression from LTBI to active TB. Global roll-out of preventive therapy will be required to achieve the World Health Organization target of TB elimination by 2050, but t…
Helen Ayles, Professor
…HCF) and were treated with standard 6-month TB regimens for drug-susceptible TB and referred for treatment according to national guidelines if they had drug-resistant disease. All TB treatment was provided by government HCF. All HIV positive individuals who presented to the clini…
Guo X, Lu J, Li J, Du W, Shen X, et al.
…ent of tuberculosis often requires a 6-month course of multidrug therapy, and for drug-resistant tuberculosis, a longer course of multidrug therapy is needed, which has many drawbacks. At present, vaccines are proposed as an adjunct to chemotherapy to protect populations with an …
Tobin EH, Tristram D
…e presence of comorbidities, the development of toxicities, drug-drug interactions, and resistance patterns of the bacterium. Resistance of tuberculosis to antibiotics is increasing, and treatment often requires the administration of novel antibiotic combinations that have underg…
Ayesha J Verrall, Philip C. Hill, Dougal Thorburn, Michael J. Maze, Lavinia Perumal, et al.
…propriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. In New …
Verrall AJ, Hill PC, Thorburn D, Maze M, Perumal L, et al.
…propriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. In New …
Mohd Fazeli bin Sazali, MD, MPH
…nt outcome, such as the increased risk of relapse, acquired drug resistant TB, treatment failure, progression of disease leading to complication, risk of death, and ongoing transmission of disease in the community. Adherence to TB therapy is critical for the success of TB treatm…
Mohammed Abdalla Rakha, Asmaa Ali, Mohmod Omer, Ahmed Alsyed, Eman Al- Anbay
…5. Moreover, we found a considerable double number of multi-drug resistance pulmonary tuberculosis and one case suspected extensive drug resistance. Conclusion: Covid 19 pandemic had a significant impact on tuberculosis care as regards diagnosis and treatment as well as follow-up…
Pennisi M, Russo G, Sgroi G, Bonaccorso A, Parasiliti Palumbo GA, et al.
…of different new bacterial strains capable to provoke multi-drug resistance phenomena. Currently, antitubercular drugs are unable to eradicate subpopulations of Mycobacterium tuberculosis (MTB) bacilli and therapeutic vaccinations have been postulated to overcome some of the crit…
Kumar V, Shankar G, Akhter Y
…bTator, we determined direction of research in the areas of drug hypersensitivity, drug resistance (AMR), and drug-related side effects. Additionally, we examined the patterns in research on Mtb metabolism and various forms of tuberculosis, including skin, brain, pulmonary, extra…
Charisse Mandimika, Gerald Friedland
…allenges in the prevention and treatment of TB/HIV disease. Drug-susceptible and drug-resistant tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics are a consequence of reactivation of latent TB infection (LTBI), treatment-related amplification of TB resistance mut…
Coad Thomas Dow, Liam Obaid
…ulmonary inflammation, and synergized with standard anti-TB drugs to enhance bacterial clearance. Additionally, DHEA and its analogues have demonstrated direct antimycobacterial activity, likely by interfering with Mtb mycolic acid synthesis, a property BEA is believed to share. …
Padmasayee Papineni
… symptoms, duration of treatment and factors that can cause drug resistance. TB-CAG knowledge of research and community engagement was an understanding that it was about finding answers to questions and gaining deeper understanding of disease and health. Participants highlighted …
Cerrone M, Bracchi M, Wasserman S, Pozniak A, Meintjes G, et al.
Introduction : Antiretroviral and anti-tuberculosis (TB) drugs are often co-administered in people living with HIV (PLWH). Early initiation of antiretroviral therapy (ART) during TB treatment improves survival in patients with advanced HIV disease. However, safety concerns relate…
Larissa Gorbach
…f Belarus were used. We used the average prices for anti-TB drugs from the International Medical Products Price Guide (2016). <b>Results:</b> The average age of a child with pulmonary TB was 14.2 ± 4.3 years. The average weight of a child with pulmonary TB was 50.8 kilograms. The…
Aliya Moreira, Dana Hassneiah, Susan E. Beekmann, Philip M. Polgreen, Maunank Shah, et al.
…nd since 2022, recommendations include 6-month regimens for drug-resistant (DR-TB) disease containing bedaquiline, linezolid, and pretomanid (BPaL) and a 4-month regimen for drug-susceptible (DS-TB) disease containing high-dose rifapentine, isoniazid, moxifloxacin, and pyrazinami…